Ilene L Hollin1, Holly L Peay2,3, Susan D Apkon4, John F P Bridges1. 1. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 2. RTI International, Research Triangle Park, North Carolina, USA. 3. Parent Project Muscular Dystrophy, Hackensack, New Jersey, USA. 4. Department of Rehabilitation Medicine, Seattle Children's Hospital and University of Washington, Seattle, Washington, USA.
Abstract
INTRODUCTION: This study quantified caregiver and patient preferences for a therapeutic agent with demonstrated pulmonary benefits for Duchenne muscular dystrophy (DMD). Caregiver and patient differences were also explored. METHODS: A best-worst scaling survey (BWS) was administered to caregivers and patients. Across 9 profiles, respondents selected the best and worst attributes. Utility scores were estimated using mixed logistic regression. RESULTS: Respondents indicated greatest preference for therapies that maintain their current level of cough strength for 10 years or for 2 years. Preference scores for risks were low: 50% chance of diarrhea and 4 additional blood draws per year. CONCLUSION: There is a strong preference for pulmonary benefit and willingness to trade off risks and burden to achieve these benefits. In exchange for maintaining cough strength for 10 years, respondents were willing to tolerate high probabilities of diarrhea and additional blood draws. Muscle Nerve 55: 626-634, 2017.
INTRODUCTION: This study quantified caregiver and patient preferences for a therapeutic agent with demonstrated pulmonary benefits for Duchenne muscular dystrophy (DMD). Caregiver and patient differences were also explored. METHODS: A best-worst scaling survey (BWS) was administered to caregivers and patients. Across 9 profiles, respondents selected the best and worst attributes. Utility scores were estimated using mixed logistic regression. RESULTS: Respondents indicated greatest preference for therapies that maintain their current level of cough strength for 10 years or for 2 years. Preference scores for risks were low: 50% chance of diarrhea and 4 additional blood draws per year. CONCLUSION: There is a strong preference for pulmonary benefit and willingness to trade off risks and burden to achieve these benefits. In exchange for maintaining cough strength for 10 years, respondents were willing to tolerate high probabilities of diarrhea and additional blood draws. Muscle Nerve 55: 626-634, 2017.
Authors: Sean Grant; Glen S Hazlewood; Holly L Peay; Ann Lucas; Ian Coulter; Arlene Fink; Dmitry Khodyakov Journal: Patient Date: 2018-04 Impact factor: 3.883
Authors: John F P Bridges; Jui-Hua Tsai; Ellen Janssen; Norah L Crossnohere; Ryan Fischer; Holly Peay Journal: Patient Date: 2019-04 Impact factor: 3.883
Authors: Alison M Barnard; Samuel L Riehl; Rebecca J Willcocks; Glenn A Walter; Amber M Angell; Krista Vandenborne Journal: J Neuromuscul Dis Date: 2020
Authors: Holly Landrum Peay; Ryan Fischer; Janice P Tzeng; Sharon E Hesterlee; Carl Morris; Amy Strong Martin; Colin Rensch; Edward Smith; Valeria Ricotti; Katherine Beaverson; Hannah Wand; Carol Mansfield Journal: PLoS One Date: 2019-05-01 Impact factor: 3.240
Authors: Rosanne Janssens; Eline van Overbeeke; Lotte Verswijvel; Lissa Meeusen; Carolien Coenegrachts; Kim Pauwels; Marc Dooms; Hilde Stevens; Steven Simoens; Isabelle Huys Journal: Front Med (Lausanne) Date: 2018-10-11
Authors: Gunnar M Buyse; Christian Rummey; Thomas Meier; Mika Leinonen; Thomas Voit; Craig M McDonald; Oscar H Mayer Journal: J Neuromuscul Dis Date: 2018